Stock Analysis

Nyxoah Full Year 2023 Earnings: €1.51 loss per share (vs €1.21 loss in FY 2022)

ENXTBR:NYXH
Source: Shutterstock

Nyxoah (EBR:NYXH) Full Year 2023 Results

Key Financial Results

  • Net loss: €43.2m (loss widened by 38% from FY 2022).
  • €1.51 loss per share (further deteriorated from €1.21 loss in FY 2022).
earnings-and-revenue-history
ENXTBR:NYXH Earnings and Revenue History March 8th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nyxoah Earnings Insights

Looking ahead, revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Belgium.

The company's shares are up 5.5% from a week ago.

Risk Analysis

Be aware that Nyxoah is showing 5 warning signs in our investment analysis and 2 of those can't be ignored...

Valuation is complex, but we're helping make it simple.

Find out whether Nyxoah is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.